Dr Reddys Laboratories Ltd Stock Price Today (NSE: DRREDDY)
Fundamental Score
Dr Reddys Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Dr Reddys Laboratories Ltd share price today is ₹1335.20, up +0.30% on NSE/BSE as of 22 May 2026. Dr Reddys Laboratories Ltd (DRREDDY) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.05L (Cr). The 52-week high for DRREDDY share price is ₹1379.70 and the 52-week low is ₹1148.40. At a P/E ratio of 18.23x, DRREDDY is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 17.96% and a debt-to-equity ratio of 0.16.
Dr Reddys Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Dr Reddys Laboratories Ltd share price chart: 8.32% return over the past month. 52-week high ₹1379.70, 52-week low ₹1148.40.
Dr Reddys Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1332.00 | ₹1345.00 | ₹1318.90 | ₹1335.20 | 24.88L (Cr) | |
| ₹1336.50 | ₹1341.90 | ₹1322.00 | ₹1331.20 | 19.27L (Cr) | |
| ₹1303.60 | ₹1344.90 | ₹1303.60 | ₹1336.70 | 39.83L (Cr) | |
| ₹1265.30 | ₹1307.70 | ₹1255.00 | ₹1303.60 | 23.63L (Cr) | |
| ₹1245.60 | ₹1303.80 | ₹1230.00 | ₹1265.30 | 92.76L (Cr) | |
| ₹1278.90 | ₹1288.30 | ₹1264.50 | ₹1270.00 | 19.46L (Cr) | |
| ₹1288.00 | ₹1299.90 | ₹1272.50 | ₹1279.90 | 15.07L (Cr) | |
| ₹1303.50 | ₹1310.20 | ₹1290.00 | ₹1293.90 | 9.65L (Cr) | |
| ₹1309.10 | ₹1315.70 | ₹1297.30 | ₹1307.60 | 25.30L (Cr) | |
| ₹1282.00 | ₹1328.60 | ₹1277.10 | ₹1311.00 | 33.40L (Cr) |
Dr Reddys Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1322.90 | ₹1345.00 | ₹1230.00 | ₹1335.20 | +0.93% | |
| ₹1280.00 | ₹1375.90 | ₹1167.50 | ₹1322.90 | +3.35% | |
| ₹1252.60 | ₹1337.30 | ₹1221.20 | ₹1254.90 | +0.18% | |
| ₹1189.50 | ₹1327.00 | ₹1167.10 | ₹1286.30 | +8.14% | |
| ₹1270.00 | ₹1270.00 | ₹1148.40 | ₹1218.10 | -4.09% | |
| ₹1263.90 | ₹1293.00 | ₹1241.30 | ₹1271.40 | +0.59% | |
| ₹1196.90 | ₹1262.40 | ₹1187.90 | ₹1258.80 | +5.17% | |
| ₹1227.90 | ₹1303.60 | ₹1180.90 | ₹1197.60 | -2.47% | |
| ₹1260.10 | ₹1326.80 | ₹1217.50 | ₹1223.70 | -2.89% | |
| ₹1258.00 | ₹1288.90 | ₹1183.40 | ₹1260.10 | +0.17% | |
| ₹1286.30 | ₹1313.40 | ₹1231.00 | ₹1270.30 | -1.24% | |
| ₹1251.00 | ₹1379.70 | ₹1232.50 | ₹1283.30 | +2.58% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Generics giant hoping for a biosimilar-led re-rating, but US pricing pressure remains a key risk.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Dr. Reddy's announced a board meeting on May 12, 2026, to review Q4FY26 and FY26 financial results. They also launched Obeda®, a generic semaglutide injection for Type 2 diabetes, priced at per month.
CORE STORY (THE REAL GAME)
Dr. Reddy's is transitioning from a generics giant to a more innovation-focused player, particularly in biosimilars and complex formulations, while maintaining a strong presence in key markets like India and Russia. The market is watching to see if they can successfully navigate pricing pressures in the US generics market and capitalize on new opportunities.
- Steady India business growth
- European generics profitability recovery
- Biosimilars pipeline potential
- Successful biosimilar launches
- Stronger-than-expected US generics performance
- Positive regulatory developments
- US generics pricing pressure
- Potential earnings miss in Q4FY26/FY27
- FII outflows from Indian equities
FII decreased holdings by 0.64%, while DII increased by 1.26%.
Indian pharma exports are growing, projected to reach $130 billion by 2030, but face supply chain issues and rising costs.
Profit converting to cash. Free Cash Flow 5Y: ₹10805.0 Cr
Next 3-6 months will be crucial to see if Dr. Reddy's can maintain its growth momentum in India and Europe, and whether its biosimilar pipeline can deliver. Watch for Q4FY26 results and FY27 guidance.
Primary Thesis Risk
Continued US generics pricing erosion could derail the earnings recovery.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Dr Reddys Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dr Reddys Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DRREDDY across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (17.96%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (22.69%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (24.30%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 18.23 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (13.26% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (22.17% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (22.28% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.16)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (24.46x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹10805.00 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 52.68%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Low Promoter Commitment (26.64%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Dr Reddys Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Dr Reddys Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Dr Reddys Laboratories LtdDr Reddys Labor...Selected✓ DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6912.00₹6912 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1409.80₹1410 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1512.80₹1513 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5470.00₹5470 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Abbott India LtdAbbott India Lt... ABBOTINDIA • 500488 | 65/100 | ₹27795.00₹27795 | ₹63358.16₹63358.16 | 41.99Average 42.0 Average | 35.68%Excellent 35.68% Excellent | 46.25%Excellent 46.25% Excellent | 0.05Excellent 0.1 Excellent | 18.98%Excellent 18.98% Excellent | 9.38%Good 9.38% Good | 1.59% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Lupin Ltd share price95148.15 Cr
Dr Reddys Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for DRREDDY — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹67.78 | ₹1271.40 | 18.8x |
| FY 2024 | ₹66.80 | ₹1388.50 | 20.8x |
| FY 2023 | ₹54.18 | ₹1159.58 | 21.4x |
| FY 2022 | ₹28.34 | ₹847.51 | 29.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Dr Reddys Laboratories Ltd Dividend History
Annual cash dividends paid by DRREDDY — dividend yield 0.63%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹666.20 Cr |
| FY 2024 | ₹664.80 Cr |
| FY 2023 | ₹497.90 Cr |
| FY 2022 | ₹414.60 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Dr Reddys Laboratories Ltd Quarterly Performance
Latest quarterly metrics for DRREDDY — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
9.83%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
7.28%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.26%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
22.28%
Compounded annual net profit growth over 5 years
Dr Reddys Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for DRREDDY — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Dr Reddys Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Dr Reddys Laboratories Ltd (DRREDDY) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Dr Reddys Laboratories Ltd
About DRREDDY (Dr Reddys Laboratories Ltd)
Dr. Reddy's Laboratories Ltd is a global pharmaceutical powerhouse, carving its niche in the intricate landscape of healthcare. They are more than just a manufacturer; they are res...earchers, innovators, and dedicated professionals striving to improve access to quality medicines worldwide. The company has a strong international presence, impacting markets across diverse regions with its expansive portfolio. Their commitment extends beyond profit margins, reflecting a genuine dedication to patient well-being and fostering a healthier future through the development, production, and distribution of impactful pharmaceutical solutions. Dr. Reddy's operates through distinct, yet interconnected divisions, each playing a vital role in the company's overall success. One segment focuses on crafting and delivering generic medications, making treatments more affordable and accessible to a wider population. Another concentrates on pharmaceutical services and active pharmaceutical ingredients, supplying the building blocks for other pharmaceutical companies to create their own formulations. This strategic combination of capabilities allows Dr. Reddy's to navigate the pharmaceutical value chain with agility and resilience, maintaining a competitive edge in a rapidly evolving industry. Dr. Reddy's unwavering focus on research and development fuels its ability to address unmet medical needs and stay ahead of the curve. They invest heavily in innovation, constantly seeking new ways to improve existing treatments and discover novel therapies for a range of diseases. This commitment to scientific advancement is deeply ingrained in the company's culture, driving its progress and solidifying its position as a trusted and respected leader in the global pharmaceutical arena. Their efforts ultimately aim to provide better healthcare solutions to those who need them most.
Company Details
Key Leadership
Corporate Events
DRREDDY Share Price: Frequently Asked Questions
What is the current share price of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd (DRREDDY) trades at ₹1335.20 on NSE and BSE. Market cap ₹1.05L (Cr). Educational data only.
What is the P/E ratio of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd has a P/E of 18.23x vs industry average 31.77x.
What is the Bull Run score for Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd has a Bull Run score of 59.2/100 based on 25+ financial parameters.
Does Dr Reddys Laboratories Ltd pay dividends?
Dr Reddys Laboratories Ltd has a dividend yield of 0.63%. Past dividends don't guarantee future payments.
What is the ROE of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd has ROE of 17.96%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd has debt-to-equity of 0.16.
Is Dr Reddys Laboratories Ltd a good investment?
Bull Run gives Dr Reddys Laboratories Ltd a score of 59.2/100. This is not investment advice — consult a SEBI-registered advisor.